Clinical trial · Observational
Prevalence of FID and QoL in Patients with Oncological and with Haematological Malignancies
Prevalence of Functional Iron Deficiency (FID) and Quality of Life (QoL) in Patients with Oncological and with Haematological Malignancies
NCT05333913CI-TRIAL-00087827completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective single-center observational study assessing prevalence of FID (Laboratory work-up) and Quality of Life (Questionnaire) in adult patients with oncological and with haematological malignancies within four weeks prior to disease-directed therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Functional Iron Deficiency | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary endpoint is the determination of the prevalence of FID in patients with oncological and with haematological malignancies.
- timeFrame
- through study completion, an average of 1 year
- description
- Prevalence of functional iron deficiency in the study population using full blood count, reticulocytes, transferrin saturation, serum-ferritin, CRP and ALAT.
Secondary outcomes (1)
- measure
- The secondary endpoint is the collection of data on quality of life using FACT-An.
- timeFrame
- through study completion, an average of 1 year
- description
- Data on quality of life using FACT-An, which covers a fatigue and anemia subscale, as well as generic QoL domains including physical well-being, functional well-being, emotional well-being and socal well-being subscales - this is done at study entry estimating scores at various subscales of FACT-An.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Patients with oncological (solid tumors) and with haematological malignancies (non-solid tumors, including Plasma cell myeloma, lymphoma, myeloproliferative neoplasias \[MPN\], myelodysplastic syndromes \[MDS\] and chronic leukemias) * Within four weeks prior to disease-directed systemic therapy * Participation in other trials is possible Exclusion Criteria: * Known iron deficiency with or without iron substitution p.o. or i.v. within last 8 weeks prior to inclusion into this trial * Therapy with RBC-transfusions within last 8 weeks prior to inclusion into this trial * Therapy with ESA within last 8 weeks prior to inclusion into this trial * Malignancies with acute need for therapeutic intervention (e.g. acute leukemias, superior vena cava obstruction, etc.) * Pregnancy * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the trial * Inability to give consent
References
Publications (0)
Data not yet available
No reference posted for this study.